Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1566316

registered interest
date	12/01/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Multiple Myeloma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the forthcoming analysis by the National Institute for Health and Care Excellence of the effectiveness of the use of CAR-T therapy for multiple myeloma, which national tariffs NICE will use for that analysis; how those tariffs were calculated; which (a) people and (b) organisations were consulted on the calculation of the tariff; and which tariffs were used by NICE in analysis of the use of CAR-T therapy for other conditions.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	122038
answer	answer is ministerial correction date of answer 18/01/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently evaluating ciltacabtagene autoleucel, a type of CAR-T therapy, within its marketing authorisation for relapsed or refractory multiple myeloma. NICE has previously evaluated other CAR-T therapies such as axicabtagene ciloleucel (Yescarta®) and tisagenlecleucel (Kymriah®) through its technology appraisal programme.</p><p>NICE’s technology appraisal process requires the manufacturer or sponsor of the technology under evaluation to produce an evidence submission that is developed in line with NICE’s preferred methods for economic evaluation (the “reference case”) as set out in its published manual for health technology evaluation. The evidence submission is then considered by NICE’s appraisal committee alongside a critique from an independent academic group and evidence from other stakeholders such as patients, clinicians and NHS England. During the ongoing appraisal of axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma, NHS England made the committee aware of a single tariff for the delivery of CAR T-cell therapies. NICE does not hold any information on who NHS England consulted on the calculation of the tariff.</p><p>NICE’s health technology evaluation manual states that the reference case “should include the full additional costs associated with introducing a technology”. The appraisal committee will consider in developing its recommendations whether the costs that are captured in the evidence submission appropriately reflect the costs to the National Health Service.</p><p>The committee papers for previous and ongoing appraisals of CAR-T therapies are available on the NICE website.</p> answering member constituency Colchester answering member printed Will Quince question first answered 18/01/2023 16:34:12 answering member 4423 label Biography information for Will Quince
tabling member	394 label Biography information for Mr Clive Betts

1566126

registered interest
date	11/01/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Multiple Myeloma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what data his Department holds on the number of countries that have approved CAR-T therapy for the treatment of multiple myeloma.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	120845
answer	answer is ministerial correction date of answer 18/01/2023 answer text <p>The information requested is not held centrally.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 120846 question first answered 18/01/2023 11:19:48 answering member 4527 label Biography information for Helen Whately
tabling member	394 label Biography information for Mr Clive Betts

1566127

registered interest
date	11/01/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Immunotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an estimate of the number of countries which have currently approved CAR-T therapy, broken down by condition.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	120846
answer	answer is ministerial correction date of answer 18/01/2023 answer text <p>The information requested is not held centrally.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 120845 question first answered 18/01/2023 11:19:48 answering member 4527 label Biography information for Helen Whately
tabling member	394 label Biography information for Mr Clive Betts

1564141

registered interest
date	06/01/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Meat: Inspections
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many of the qualified meat inspectors working for the Food Standards Agency are employees; and how many of these are (a) permanent, (b) temporary, (c) casual and (d) agency employees.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	117461
answer	answer is ministerial correction date of answer 11/01/2023 answer text <p>There is a total of 659, including 57 casuals, qualified meat hygiene inspectors employed by the Food Standards Agency and our contractor. Of the 314 qualified meat hygiene inspectors employed by the Food Standards Agency, 296 are permanent and 18 are casual, paid an hourly rate of between £13.99 to £18.00 per hour. 306 qualified meat hygiene inspectors are employed by a contractor including 39 casuals. The information on the hourly rate of pay is unavailable as it is commercially sensitive.</p> answering member constituency Harborough answering member printed Neil O'Brien grouped question UIN 117462 question first answered 11/01/2023 12:38:35 answering member 4679 label Biography information for Neil O'Brien
tabling member	394 label Biography information for Mr Clive Betts

1564142

registered interest
date	06/01/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Meat: Inspections
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what is the hourly rate of pay for (a) employed and (b) agency trained meat inspectors at the Food Standard Agency.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	117462
answer	answer is ministerial correction date of answer 11/01/2023 answer text <p>There is a total of 659, including 57 casuals, qualified meat hygiene inspectors employed by the Food Standards Agency and our contractor. Of the 314 qualified meat hygiene inspectors employed by the Food Standards Agency, 296 are permanent and 18 are casual, paid an hourly rate of between £13.99 to £18.00 per hour. 306 qualified meat hygiene inspectors are employed by a contractor including 39 casuals. The information on the hourly rate of pay is unavailable as it is commercially sensitive.</p> answering member constituency Harborough answering member printed Neil O'Brien grouped question UIN 117461 question first answered 11/01/2023 12:38:35 answering member 4679 label Biography information for Neil O'Brien
tabling member	394 label Biography information for Mr Clive Betts

1563034

registered interest
date	19/12/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Advanced Therapy Medicinal Products
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to change (a) NICE and (b) NHS England’s processes to help adapt to developing cell and gene therapies.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	113164
answer	answer is ministerial correction date of answer 10/01/2023 answer text <p>National Institute for Health and Care Excellence (NICE) carried out a comprehensive review of its methods and processes in early 2022. The changes introduced will ensure its methods and processes are suited to new and emerging types of technology, including cell and gene therapies, and provide more equitable access (to these technologies) for those with severe diseases.</p><p> </p><p>As committed to under Action 12 of England Rare Diseases Action Plan 2022, NHS England are developing a strategic approach for gene therapies and other advanced therapy medicinal products based on horizon scanning. This work is ongoing and the Department will receive an update on progress and next steps ahead of publication of the action plan, due in early 2023.</p> answering member constituency Colchester answering member printed Will Quince question first answered 10/01/2023 09:06:04 answering member 4423 label Biography information for Will Quince
tabling member	394 label Biography information for Mr Clive Betts

1563035

registered interest
date	19/12/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what advice he has received on the potential impact of medical innovation in the NHS on global research and development investment decisions; and if he will make a statement.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	113165
answer	answer is ministerial correction date of answer 10/01/2023 answer text <p>The Government’s Life Sciences Vision, published in July 2021, sets out our ambition to stimulate the United Kingdom’s life sciences sector. The Vision commits the Government to supporting the National Health Service to test, purchase and spread innovative technologies more effectively, to result in cutting-edge science and innovations being embedded widely across the NHS, as early as possible, and rapidly adopted across the rest of the world.</p><p>We are working with industry and system partners to make the NHS the country’s most powerful driver of innovation. This work is overseen by the Life Science Council, chaired by the Secretaries of State for the Department of Health and Social Care and the Department for Business, Energy and Industrial Strategy, and driven through the Life Sciences Vision Delivery Board, chaired by Ministers within the departments. We will continue to work closely with a wide range of public and private sector bodies and stakeholders across the sector to deliver the Life Sciences Vision.</p> answering member constituency Colchester answering member printed Will Quince question first answered 10/01/2023 09:08:23 answering member 4423 label Biography information for Will Quince
tabling member	394 label Biography information for Mr Clive Betts

1563036

registered interest
date	19/12/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Advanced Therapy Medicinal Products
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps they are taking to encourage clinical trials for cell and gene therapy.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	113166
answer	answer is ministerial correction date of answer 10/01/2023 answer text <p>The National Institute for Health and Care Research (NIHR) provides investment to support multiple organisations in encouraging clinical trials across all specialities. This includes 20 NIHR Biomedical Research Centres and 28 NIHR Clinical Research Facilities across England which have the capacity and expertise to deliver clinical trials for cell and gene therapies.</p><p>NHS Blood and Transplant also operate three advanced therapy units to support cell therapies and are building a new Clinical Biotechnology Centre to increase the United Kingdom’s ability to develop new gene therapies. Innovate UK has also established the Cell and Gene Therapy Catapult to help companies, researchers and innovators throughout development, manufacturing and clinical adoption, to accelerate the process of cell and gene therapies coming to market</p> answering member constituency Colchester answering member printed Will Quince question first answered 10/01/2023 09:09:14 answering member 4423 label Biography information for Will Quince
tabling member	394 label Biography information for Mr Clive Betts

1463693

registered interest
date	17/05/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to notify immunocompromised people who are eligible for a covid-19 spring booster vaccination; and which part of the NHS is responsible for informing those people.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	3471
answer	answer is ministerial correction date of answer 13/06/2022 answer text <p>Individuals aged 12 years old and over who are immunosuppressed are eligible to receive a spring booster dose. Local National Health Service systems are responsible for inviting eligible individuals with appointments available online through the National Booking Service or via 119.</p><p>The NHS and charity and community leaders have published an open letter to encourage people with a weakened immune system to receive their COVID-19 vaccinations, which is available at the following link:</p><p><a href="https://www.england.nhs.uk/2022/05/open-letter-from-nhs-charity-and-community-leaders-to-people-with-a-weakened-immune-system/" target="_blank">https://www.england.nhs.uk/2022/05/open-letter-from-nhs-charity-and-community-leaders-to-people-with-a-weakened-immune-system/</a></p> answering member constituency Erewash answering member printed Maggie Throup question first answered 13/06/2022 16:07:34 answering member 4447 label Biography information for Maggie Throup previous answer version 2202 answering member constituency Erewash answering member printed Maggie Throup answering member 4447 label Biography information for Maggie Throup
tabling member	394 label Biography information for Mr Clive Betts

1452500

registered interest
date	18/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Test and Trace Support Payment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, for what reason people who were tested at a covid-19 test site that used LAMP tests and subsequently tested positive are not eligible for Test and Trace Support Payments but people who received a positive result from a PCR test are eligible for those payments.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	142431
answer	answer is ministerial correction date of answer 23/03/2022 answer text <p>LAMP testing has not been used widely for the general public. However, the UK Health Security Agency informed local authorities that applicants who test positive for COVID-19 via this route should receive the £500 support payment, provided they met the other eligibility criteria. The scheme closed on 24 February 2022.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 23/03/2022 17:42:12 answering member 4447 label Biography information for Maggie Throup
tabling member	394 label Biography information for Mr Clive Betts